logo

For the Inventor, By the Inventor

Watertown, MA, United States of America

Kymera Therapeutics, Inc.


USPTO Granted Patents = 48


Trademarks = 3

Forward Citations = 284

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Nan Ji (30 out of 54 patents)

silverMedal Yi Zhang (28 out of 34 patents)

bronzeMedal Matthew M Weiss (26 out of 58 patents)

4.  Nello Mainolfi (23 out of 44 patents)

5.  Xiaozhang Zheng (17 out of 114 patents)

6.  Arthur F Kluge (15 out of 96 patents)

7.  Xiao Zhu (11 out of 17 patents)

8.  Paul R Fleming (6 out of 6 patents)

9.  Bin Yang (3 out of 3 patents)

10.  Haojing Rong (3 out of 3 patents)

11.  Michael D Sintchak (2 out of 11 patents)

12.  Duncan Walker (1 out of 10 patents)

13.  Arthur F Fluge (1 out of 1 patent)

14.  Don Corson (1 out of 1 patent)

15.  Jeffrey Davis (1 out of 4 patents)


Core Competencies:
Protein Degraders
IRAK Degraders
SMARCA Degraders
CRBN Ligands
MDM2 Degraders
CDK2 Degraders
STAT Degraders
Tricyclic CRBN Ligands
IRAK4 Degraders
Deuterated IRAK Degraders
Mutant Lymphomas
Crystalline Forms

48 patents:

1. 12753172 - Double degraders and uses thereof (2026-10-06),
2. 12715877 - Protein degraders and uses thereof (2026-08-25),
3. 12655159 - Deuterated IRAK degraders and uses thereof (2026-06-16),
4. 12624044 - SMARCA degraders and uses thereof (2026-05-12),
5. 12606568 - SMARCA degraders and uses thereof (2026-04-21),
6. 12569485 - SMARCA inhibitors and uses thereof (2026-03-10),
7. 12558427 - IRAK degraders and uses thereof (2026-02-24),
8. 12551564 - IRAK degraders and uses thereof (2026-02-17),
9. 12545659 - IRAK degraders and uses thereof (2026-02-10),
10. 12540127 - CRBN ligands and uses thereof (2026-02-03),
11. 12539295 - IRAK degraders and uses thereof (2026-02-03),
12. 12528785 - MDM2 degraders and uses thereof (2026-01-20),
13. 12521438 - SMARCA degraders and uses thereof (2026-01-13),
14. 12516068 - Protein degraders and uses thereof (2026-01-06),
15. 12497402 - IRAK4 degraders and uses thereof (2025-12-16),
Company Overview
Kymera Therapeutics, Inc. is a biotechnology company based in Watertown, MA, specializing in the development of innovative therapeutics that harness the body's natural protein degradation pathways. The company focuses on targeted protein modulation to address a range of diseases, including cancer and autoimmune disorders. By leveraging its proprietary technology platform, Kymera aims to create transformative treatments that offer new hope for patients with unmet medical needs, positioning itself at the forefront of the biopharmaceutical industry.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Kymera Therapeutics, Inc. USPTO Patent Assignee Logo
48 Patents

#11 in Watertown, MA

#405 in Massachusetts

#7,284 in US

#14,550 in the World

Watertown, MA (US)
Watertown, MA, United States of America

Kymera Therapeutics, Inc.

Forward Citations = 284

25 inventors:

goldMedal Nan Ji (30 out of 54 patents)

silverMedal Yi Zhang (28 out of 34 patents)

bronzeMedal Matthew M Weiss (26 out of 58 patents)

4.  Nello Mainolfi (23 out of 44 patents)

5.  Xiaozhang Zheng (17 out of 114 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kymera Therapeutics, Inc.. Retrieved from https://idiyas.com/company/kymera-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…